Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bond3D is a Dutch technology company specializing in the additive manufacturing of high-performance polymers, most notably PEEK (Polyether ether ketone). Founded in 2014 and headquartered in Enschede, the company utilizes a patented pressure-controlled extrusion process to produce 100% voidless, isotropic parts that match the mechanical properties of injection-molded components. Bond3D's technology is particularly transformative for the medical device industry, enabling the production of patient-specific, porous implants such as spinal cages and cranial implants that promote bone ingrowth. In December 2024, the company was acquired by the Demcon group to further scale its R&D and manufacturing capabilities. Bond3D maintains strategic partnerships with material leaders like Victrex and Invibio to accelerate the adoption of 3D-printed high-performance polymers in critical applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bond High Performance 3D Technology.